Transaction log

  • Mar 19, 2020 - Bought 10 @ $211.90 (2.67% wtg, coffee can)

  • Jun 10, 2020 - Sold 4 @ $358.00 (6 shares, 1.86% wtg)

Illumina

Location: San Diego, California

 

Profile

Industry: Diagnostics & research

Sector: Health care

Theme: Genomic revolution

5-Year shareholder growth: 0.4%/year

Estimated fair value: $154

Valuation assumption: 25 x annual R&D

Insider ownership: 2.6%

Investors: Tom Slater (Baillie Gifford)

Estimated fair value history

  • Dec-24 - $177 (25 x R&D)

  • Mar-25 - $165

  • Jun-25 - $154

History
Icahn attacks Illumina
Icahn attacks Illumina

Considering the importance of Illumina to the genomics ecosystem, its past success and role in driving down gene sequencing costs almost singlehandedly, I’m giving them the benefit of the doubt on the Grail acquisition. [mailbag]

Robinhood traders are out of control
Robinhood traders are out of control

"Never confuse brains with a bull market." That's exactly what Millennial traders are doing these days. [trades]

In a crash, cash is king
In a crash, cash is king

If you think the world is not coming to an end (my best guess), it's probably time to buy quality retailers at bargain prices. This too shall pass and the sun will come out. [trades]